Study #2023-0747
A phase 2 trial to assess safety and efficacy of tofacitinib 2% cream in the treatment of cutaneous T-cell lymphoma (CTCL), stages IA, IB, and IIA
MD Anderson Study Status
Enrolling
Treatment Agent
tofacitinib 2% cream
Description
To study the safety and effectiveness of tofacitinib 2% cream in treating early-stage CTCL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cutaneous T-Cell Lymphoma
Study phase:
Phase II
Physician name:
Julia Dai
Department:
Dermatology
For general questions about clinical trials:
1-855-927-2548
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.